inclusion criteria: 1. provision of informed consent 2. male or female patients aged ≥18 years 3. currently hospitalized 4. hospital admission no more than 4 days prior to screening 5. confirmed severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infection by laboratory testing within 10 days prior to screening, or strongly suspected sars-cov-2 infection on presentation 6. chest radiography or computerized tomography (ct) findings that, in the opinion of the investigator, are consistent with coronavirus disease 2019 (covid-19) 7. blood oxygen saturation (spo2) ≥ 94% while receiving low-flow supplemental oxygen (5 liters or less) 8. medical history of at least one of the following: 1. hypertension 2. type 2 diabetes 3. atherosclerotic cardiovascular disease 4. heart failure (with either reduced or preserved left ventricular ejection fraction (lvef)) 5. chronic kidney disease stage 3 to 4 (estimated glomerular filtration rate (egfr) between 25 to 60 ml/min/1.73 m2) key

inclusion criteria: 1. provision of informed consent 2. male or female patients aged ≥18 years 3. currently hospitalized 4. hospital admission no more than 4 days prior to screening 5. confirmed severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infection by laboratory testing within 10 days prior to screening, or strongly suspected sars-cov-2 infection on presentation 6. chest radiography or computerized tomography (ct) findings that, in the opinion of the investigator, are consistent with coronavirus disease 2019 (covid-19) 7. blood oxygen saturation (spo2) ≥ 94% while receiving low-flow supplemental oxygen (5 liters or less) 8. medical history of at least one of the following: 1. hypertension 2. type 2 diabetes 3. atherosclerotic cardiovascular disease 4. heart failure (with either reduced or preserved left ventricular ejection fraction (lvef)) 5. chronic kidney disease stage 3 to 4 (estimated glomerular filtration rate (egfr) between 25 to 60 ml/min/1.73 m2) key

inclusion criteria: provision of informed consent male or female patients aged ≥18 years currently hospitalized hospital admission no more than 4 days prior to screening confirmed severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infection by laboratory testing within 10 days prior to screening, or strongly suspected sars-cov-2 infection on presentation chest radiography or computerized tomography (ct) findings that, in the opinion of the investigator, are consistent with coronavirus disease 2019 (covid-19) blood oxygen saturation (spo2) ≥ 94% while receiving low-flow supplemental oxygen (5 liters or less) medical history of at least one of the following: hypertension type 2 diabetes atherosclerotic cardiovascular disease heart failure (with either reduced or preserved left ventricular ejection fraction (lvef)) chronic kidney disease stage 3 to 4 (estimated glomerular filtration rate (egfr) between 25 to 60 ml/min/1.73 m2) key

inclusion criteria: provision of informed consent male or female patients aged ≥18 years currently hospitalized hospital admission no more than 4 days prior to screening confirmed severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infection by laboratory testing within 10 days prior to screening, or strongly suspected sars-cov-2 infection on presentation chest radiography or computerized tomography (ct) findings that, in the opinion of the investigator, are consistent with coronavirus disease 2019 (covid-19) blood oxygen saturation (spo2) ≥ 94% while receiving low-flow supplemental oxygen (5 liters or less) medical history of at least one of the following: hypertension type 2 diabetes atherosclerotic cardiovascular disease heart failure (with either reduced or preserved left ventricular ejection fraction (lvef)) chronic kidney disease stage 3 to 4 (estimated glomerular filtration rate (egfr) between 25 to 60 ml/min/1.73 m2) key

inclusion criteria: provision of informed consent male or female patients aged ≥18 years currently hospitalized hospital admission no more than 4 days prior to screening confirmed sars-cov-2 infection by laboratory testing within 10 days prior to screening, or strongly suspected sars-cov-2 infection on presentation chest radiography or ct findings that, in the opinion of the investigator, are consistent with covid-19 spo2 ≥ 94% while receiving low-flow supplemental oxygen (5 liters or less) medical history of at least one of the following: hypertension t2dm atherosclerotic cardiovascular disease heart failure (with either reduced or preserved lvef) ckd stage 3 to 4 (egfr between 25 to 60 ml/min/1.73 m2) key

inclusion criteria: provision of informed consent male or female patients aged ≥18 years currently hospitalized hospital admission no more than 4 days prior to screening confirmed sars-cov-2 infection by laboratory testing within 10 days prior to screening, or strongly suspected sars-cov-2 infection on presentation chest radiography or ct findings that, in the opinion of the investigator, are consistent with covid-19 spo2 ≥ 94% while receiving low-flow supplemental oxygen (5 liters or less) medical history of at least one of the following: hypertension t2dm atherosclerotic cardiovascular disease heart failure (with either reduced or preserved lvef) ckd stage 3 to 4 (egfr between 25 to 60 ml/min/1.73 m2) key

inclusion criteria: 1. provision of informed consent 2. male or female patients aged ≥18 years 3. currently hospitalized 4. hospital admission no more than 4 days prior to screening 5. confirmed sars-cov-2 infection by laboratory testing within 10 days prior to screening, or strongly suspected sars-cov-2 infection on presentation 6. chest radiography or ct findings that, in the opinion of the investigator, are consistent with covid-19 7. spo2 ≥ 94% while receiving low-flow supplemental oxygen (5 liters or less) 8. medical history of at least one of the following: 1. hypertension 2. t2dm 3. atherosclerotic cardiovascular disease 4. heart failure (with either reduced or preserved lvef) 5. ckd stage 3 to 4 (egfr between 25 to 60 ml/min/1.73 m2) key

inclusion criteria: 1. provision of informed consent 2. male or female patients aged ≥18 years 3. currently hospitalized 4. hospital admission no more than 4 days prior to screening 5. confirmed sars-cov-2 infection by laboratory testing within 10 days prior to screening, or strongly suspected sars-cov-2 infection on presentation 6. chest radiography or ct findings that, in the opinion of the investigator, are consistent with covid-19 7. spo2 ≥ 94% while receiving low-flow supplemental oxygen (5 liters or less) 8. medical history of at least one of the following: 1. hypertension 2. t2dm 3. atherosclerotic cardiovascular disease 4. heart failure (with either reduced or preserved lvef) 5. ckd stage 3 to 4 (egfr between 25 to 60 ml/min/1.73 m2) key

inclusion criteria: 1. provision of informed consent 2. male or female patients aged ≥18 years 3. currently hospitalized 4. hospital admission no more than 4 days prior to screening 5. confirmed sars-cov-2 infection by laboratory testing within 10 days prior to screening, or strongly suspected sars-cov-2 infection on presentation 6. chest radiography or ct findings that, in the opinion of the investigator, are consistent with covid-19 7. mild-moderate disease: spo2≥94% with low-flow supplemental oxygen (5 liters or less) 8. medical history of at least one of the following: 1. hypertension 2. t2dm 3. atherosclerotic cardiovascular disease 4. heart failure (with either reduced or preserved lvef) 5. ckd stage 3 to 4 (egfr between 25 to 60 ml/min/1.73 m2) key

inclusion criteria: 1. provision of informed consent 2. male or female patients aged ≥18 years 3. currently hospitalized 4. hospital admission no more than 4 days prior to screening 5. confirmed sars-cov-2 infection by laboratory testing within 10 days prior to screening, or strongly suspected sars-cov-2 infection on presentation 6. chest radiography or ct findings that, in the opinion of the investigator, are consistent with covid-19 7. mild-moderate disease: spo2≥94% with low-flow supplemental oxygen (5 liters or less) 8. medical history of at least one of the following: 1. hypertension 2. t2dm 3. atherosclerotic cardiovascular disease 4. heart failure (with either reduced or preserved lvef) 5. ckd stage 3 to 4 (egfr between 25 to 60 ml/min/1.73 m2) key